NEFL and myeloid sarcoma: Several studies have supported the paradigm that serum NfL levels may further assist in the management of MS by helping predict new disease activity, correlating with future brain atrophy, portending poorer prognosis, and by assessing response to DMT [15,16,17,18,19,20,21,22].